Abstract: Smart dental implant systems and methods for ambulatory dental care are provided. In some embodiments, the disclosed subject matter includes a crown, adapted to mimic a patient's anatomy and location of the smart dental implant system. The crown can include piezoelectric nanoparticles, disposed on a surface of the crown and adapted to generate electricity from a patient's oral motion. In some embodiments, the disclosed subject matter includes an abutment, coupled to the crown. The abutment can include an energy harvesting circuit, operationally coupled to the piezoelectric nanoparticles and adapted to harvest the electricity, and a micro LED array, operationally coupled to the energy harvesting circuit and adapted to photobiomodulate surrounding peri-implant soft tissue.

Abstract: A behavioral malware detection involves extracting features from prefetch files, wherein prefetch files; classifying and detecting benign applications from malicious applications using the features of the prefetch files; and quarantining malicious applications based on the detection.

Abstract: A method for treating or preventing a disease or condition that operates by calcium transport through the mitochondrial calcium uniporter (MCU), the method comprising administering to a subject a therapeutically effective amount of an MCU inhibitor having the following structure: wherein L1, L2, L3, L4, L5, L6, L7, L8, X1, and X2 are independently selected from halide, amine groups —NR1R2R3, phosphine groups —PR5R6R7, carboxylate groups R4C(O)O—, and solvent molecules, and provided that at least one of L1, L2, L3, L4, L5, L6, L7, L8, X1, and X2 is selected from amine or phosphine groups; wherein R1, R2, R3, and R4 are independently selected from hydrogen atoms and hydrocarbon groups having up to six carbon atoms, wherein two of R1, R2, and R3 within a —NR1R2R3 group are optionally interconnected to form an N-containing ring; and R groups in adjacent amino or phosphine groups may optionally interconnect.

Abstract: Provided herein are methods of detecting a target nucleic acid sequence. In one embodiment, the method includes contacting genomic DNA with a guide RNA having a portion complementary to the target sequence in the genomic DNA and with Cas9 nickase to produce a single-strand break in the genomic DNA at a specific location adjacent to the target sequence. The method further includes contacting the nicked DNA with a polymerase and fluorescently labeled nucleotide. The fluorescently labeled nucleotide is incorporated into the nicked DNA at the specific location and the target nucleic acid sequence is detected via fluorescent label.

Abstract: A method for treating or preventing a disease or condition that operates by calcium transport through the mitochondrial calcium uniporter (MCU), the method comprising administering to a subject a therapeutically effective amount of an MCU inhibitor having the following structure: wherein L1, L2, L3, L4, L5, L6, L7, L8, X1, and X2 are independently selected from halide, amine groups —NR1R2R3, phosphine groups —PR5R6R7, carboxylate groups R4C(O)O—, and solvent molecules, and provided that at least one of L1, L2, L3, L4, L5, L6, L7, L8, X1, and X2 is selected from amine or phosphine groups; wherein R1, R2, R3, and R4 are independently selected from hydrogen atoms and hydrocarbon groups having up to six carbon atoms, wherein two of R1, R2, and R3 within a —NR1R2R3 group are optionally interconnected to form an N-containing ring; and R groups in adjacent amino or phosphine groups may optionally interconnect.

Abstract: A behavioral malware detection involves extracting features from prefetch files, wherein prefetch files; classifying and detecting benign applications from malicious applications using the features of the prefetch files; and quarantining malicious applications based on the detection.

Abstract: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.

Abstract: The present application provides an external thermionic cathode distributed x-ray apparatus, including a vacuum box which is sealed at its periphery, where the interior thereof is high vacuum; a plurality of electron transmitting units arranged in a linear array and installed on the side wall of the vacuum box, where each electron transmitting unit is independent to each other; an anode installed in the center inside the vacuum box, where in the direction of length, the anode is parallel to the orientation of the electron transmitting unit, and in the direction of width, the anode has a predetermined angle with respect to the plane of the electron transmitting unit; a power supply and control system having a high voltage power supply and a focusing power supply; and a transmitting control means and a control system.

Abstract: The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3?untranslated region (3?UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy.

Abstract: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.

Abstract: The invention provides a novel antigen, MPD6, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3? untranslated region (3?UTR) of myotrophin mRNA. MPD6 elicits IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES mediated translation, but not myotrophin-MPD6 transcription, was significantly upregulated in response to IFN-? stimulation. These findings demonstrate that a novel IRES-mediated mechanism is responsible for the translation of unconventional self-antigen MPD6 in responsive to IFN-? stimulation. The eliciting anti-tumor immune response against unconventional antigen MPD6 in patients with myeloproliferative diseases indicates MPD6 as a target of novel immunotherapy.

Abstract: The invention provides osteoactivin proteins and nucleic acid molecules that encode the same, as well as biologically functional expression vectors containing nucleic acid molecules encoding osteoactivin proteins, and antibodies specific for osteoactivin proteins. The invention also provides therapeutic and diagnostic compositions and methods for utilizing the proteins, antibodies, nucleic acids, and vectors of the invention, for example, to modulate bone formation.

Abstract: Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length and comprise a sequence which is at least 80% identical, preferably at least 90% identical to the amino acid sequence of a fragment contained within domain III of DBP. Methods for promoting bone deposition in a subject in need of the same are also provided. The methods comprise administering to the subject a therapeutically effective quantity of an agent selected from the group consisting of an activated form of vitamin D binding protein referred to hereinafter as “ADBP”, one or more DBP peptides, and combinations thereof. The agents may be administered locally or systemically.

Abstract: Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length and comprise a sequence which is at least 80% identical, preferably at least 90% identical to the amino acid sequence of a fragment contained within domain III of DBP. Methods for promoting bone deposition in a subject in need of the same are also provided. The methods comprise administering to the subject a therapeutically effective quantity of an agent selected from the group consisting of an activated form of vitamin D binding protein referred to hereinafter as “ADBP”, one or more DBP peptides, and combinations thereof. The agents may be administered locally or systemically.

Abstract: The present invention relates to microcapsules comprising a wall and an aqueous core comprising various active agents, and prepared by the interfacial reaction in aqueous medium of Lewis acid and base wall-forming reactants.

Abstract: A tablet for the controlled release of an active pharmaceutical ingredient. The tablet comprises a core having a donut-like configuration with a cylindrical hole extending through the center of the core. The core of the body comprises at least one active pharmaceutical agent and at least one hydrophilic, water-soluble, polymeric carrier. The core is coated with a hydrophobic, water-insoluble material covering all of the core except that which is defined by the cylindrical hole. Also included is a method of preparing a tablet for the controlled release of an active ingredient. The method comprises the steps of blending an active pharmaceutical ingredient, a water-soluble hydrophilic, polymeric carrier, and optionally an excipient, to form a mix; compressing the mix; punching a tablet from the mix; coating the tablet in a water insoluble, hydrophobic coating, then drilling a hole through the coated tablet.

Abstract: A swellable hydrophillic matrix tablet that delivers drugs in a controlled manner over a long period of time and is easy to manufacture. More specifically, the drug is disposed in a matrix composed of HPMC or polyethylene oxide, in the presence of a salt, which may be a combination of salts. Suitable salts include sodium bicarbonate, sodium chloride, potassium bicarbonate, calcium chloride, sodium bisulfate, sodium sulfite, and magnesium sulfate. Outward diffusion of the drug is controlled by an inwardly progressing hardening reaction between the salt and the dissolution medium, possibly also involving the drug itself.

Abstract: A controlled release tablet including a pharmaceutical agent and an excipient. The excipient includes at least about 60% of a water swellable polymer and a lubricant. The water swellable polymer is chosen such that the swelling rate of the polymer is equal to the dissolution rate of the swollen polymer. The excipient may also include such other ingredients as diluents, fillers, binders, solubilizers, emulsifiers, and other pharmacologically inactive compounds. The polymer is chosen with the pharmaceutical agent in mind such that the tablet will be fully dissolved at the same time that the last of the pharmaceutical agent is released.

Abstract: Methods and products are provided for producing and/or purifying virtually any hybrid polypeptide molecule employing recombinant DNA techniques. More specifically, a DNA fragment coding for a protein molecule, e.g. a polypeptide or portion thereof, is fused to a DNA fragment coding for a binding protein, such as the gene coding for the maltose binding protein. The fused DNA is inserted into a cloning vector and an appropriate host transformed. Upon expression, a hybrid polypeptide is produced which can be purified by contacting the hybrid polypeptide with a ligand or substrate to which the binding protein has specific affinity, e.g. by affinity chromatography. The hybrid polypeptide so purified may in certain instances be useful in its hybrid form, or it may be cleaved to obtain the protein molecule itself by, for example, linking the DNA fragments coding for the target and binding proteins with a DNA segment which codes for a peptide which is recognized and cut by a proteolytic enzyme, such as Factor Xa.

Abstract: A method and system for displaying a function in two dimensions where the function is made up of numerous independent variables and at least one dependent variable. A new independent variable value can be defined having values which correspond to the multiple dependent variables. The variable values are read into a computer and the independent variables are then ranked by the user from fastest- to slowest-running variable. Each dependent variable corresponding to the new independent variable is plotted along the Y-axis. The independent variable values are plotted along the X-axis in a hierarchical manner. The hierarchical manner involves a nesting of fastest-running variables within slower-running variables. Rectangles are then drawn to correspond to each variable value. Each rectangle horizontally encloses the faster-running variables associated with it.